Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance

Clinical Infectious Diseases

Volumn 62, Issue 4, 2015, Pages 418-430

  Cegielski, J Peter ^a   Kurbatova, Ekaterina ^a   Van Der Walt, Martie ^c   Brand, Jeannette ^c   Ershova, Julia ^a   Tupasi, Thelma ^d   Caoili, Janice Campos ^d   Dalton, Tracy ^a   Contreras, Carmen ^e   Yagui, Martin ^b   Bayona, Jaime ^e   Kvasnovsky, Charlotte ^a   Leimane, Vaira ^f   Kuksa, Liga ^f   Chen, Michael P ^a   Via, Laura E ^b   Hwang, Soo Hee ^g   Wolfgang, Melanie ^a   Volchenkov, Grigory V ⁱ   Somova, Tatiana ⁱ   Smith, Sarah E ^a   Akksilp, Somsak ^l   Wattanaamornkiet, Wanpen ^m   Kim, Hee Jin ^h   Kim, Chang Ki ^h   Kazennyy, Boris Y ^j   Khorosheva, Tatiana ^j   Kliiman, Kai ⁿ   Viiklepp, Piret ^o   Jou, Ruwen ^p   Huang, Angela Song En ^p   Vasilyeva, Irina A ^k   Demikhova, Olga V ^k   Lancaster, Joey ^c   Odendaal, Ronel ^c   Diem, Lois ^a   Tan, Kathrine ^a   Walker, Allison Taylor ^a   Sigman, Erika ^a   Metchock, Beverly ^a   Perez, M Therese C ^d   Gler, M Tarcela ^d   Bonilla, Cesar ^q   Jave, Oswaldo ^q   Asencios, Luis ^r   Yale, Gloria ^r   Suarez, Carmen ^s   Norvaisha, Inga ^f   Skenders, Girts ^f   Sture, Ingrida ^f   Riekstina, Vija ^f   Cirule, Andra ^f   Cho, Sang Nae ^t   Eum, Seokyong ^t   Lee, Jongseok ^t   Park, Seungkyu ^g   Jeon, Doosoo ^g   Cai, Ying ^b   Shamputa, Isdore C ^b   Kuznetsova, Tatiana ⁱ   Akksilp, Rattanawadee ^m   Sitti, Wanlaya ^m   Inyapong, Jirapan ^m   Kiryanova, Elena V ^j   Degtyareva, Irina ^j   Nemtsova, Evgenia S ^j   Levina, Klavdia ^u   Danilovits, Manfred ⁿ   Kummik, Tiina ⁿ   Lei, Yung Chao ^p   Huang, Wei Lun ^p   Erokhin, Vladislav V ^k   Chernousova, Larisa N ^k   Andreevskaya, Sofia N ^k   Larionova, Elena E ^k   Smirnova, Tatyana G ^k   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d Tropical Disease Foundation   (Philippines)

^e Socios en Salud Sucursal   (Peru)

^f RIGA EAST UNIVERSITY HOSPITAL   (Latvia)

^g Masan National Hospital   (South Korea)

^h Korean Institute of Tuberculosis   (South Korea)

ⁱ Vladimir Oblast Tuberculosis Dispensary   (Russian Federation)

^j Orel Oblast Tuberculosis Dispensary   (Russian Federation)

^k CENTRAL TUBERCULOSIS RESEARCH INSTITUTE   (Russian Federation)

^l MINISTRY OF PUBLIC HEALTH   (Thailand)

^m Office of Disease Prevention and Control 7   (Thailand)

ⁿ TARTU UNIVERSITY HOSPITAL   (Estonia)

^o NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^p CENTER FOR DISEASE CONTROL   (Taiwan)

^q National TB Strategy   (United Kingdom)

^r Lima City Health District Reference Laboratory   (Peru)

^s Lima East Health District Reference Laboratory   (Peru)

^t Yonsei University College of Medicine   (South Korea)

^u North Estonia Regional Hospital   (Estonia)

more..

Author keywords

acquired drug resistance; extensively drug resistant tuberculosis; multidrug resistant tuberculosis; second line drugs; treatment outcome

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; THIOAMIDE; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFICACY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SPUTUM CULTURE; TREATMENT OUTCOME; ADOLESCENT; AGED; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84952985566     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ910     Document Type: Article

References (23)

1. World Health Organization. Global tuberculosis report 2014. Geneva, Switzerland: World Health Organization, 2014.
2. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR 2006; 55:301-5.
3. Shah NS, Wright A, Bai G-H, et al. Worldwide emergence of extensively drugresistant tuberculosis. Emerg Infect Dis 2007; 13:380-7.
4. Dalton T, Cegielski P, Akksilp S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012; 380:1406-17.
5. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20:810-4.
6. Cegielski JP, Dalton T, Yagui M, et al. Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2014; 59:1049-63.
7. Shin S, Keshavjee S, Gelmanova I, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med 2010; 182:426-32.
8. Ershova J, Kurbatova E, Moonan P, Cegielski JP. Acquired resistance to secondline drugs among persons with tuberculosis in the United States. Clin Infect Dis 2012; 55:1600-7.
9. Cavanaugh JS, Kazennyy BY, Nguyen ML, et al. Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005. Int J Tuberc Lung Dis 2012; 16:1069-74.
10. Kent PT, Kubica GP. Public health mycobacteriology a guide for the level III laboratory. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control, 1985.
11. Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. 2nd ed. CLSI document M24-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2011.
12. Cowan LS, Mosher L, Diem L, Massey JP, Crawford JT. Variable-number tandem repeat typing of Mycobacterium tuberculosis isolates with low copy numbers of IS6110 by using mycobacterial interspersed repetitive units. J Clin Microbiol 2002; 40:1592-602.
13. Supply P, Allix C, Lesjean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44:4498-510.
14. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9:640-5.
15. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update 2008. Geneva, Switzerland: World Health Organization, 2008.
16. Tierney DB, Franke MF, Becerra MC, et al. Time to culture conversion and regimen composition in multidrug-resistant tuberculosis treatment. PLoS One 2014; 9: e108035.
17. Velásquez GE, Becerra MC, Gelmanova IY, et al. Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. Clin Infect Dis 2014; 59:9-15.
18. Mitnick CD, Franke MF, Rich ML, et al. Aggressive regimens for multidrugresistant tuberculosis decrease all-cause mortality. PLoS One 2013; 8:e58664.
19. Franke MF, Appleton SC, Mitnick CD, et al. Aggressive regimens for multidrugresistant tuberculosis reduce recurrence. Clin Infect Dis 2013; 56:770-6.
20. Ershova JV, Kurbatova EV, Moonan PK, Cegielski JP. Mortality among tuberculosis patients with acquired resistance to second-line antituberculosis drugs-United States, 1993-2008. Clin Infect Dis 2014; 59:465-72.
21. Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data metaanalysis of 9,153 patients. PLoS Med 2012; 9:e1001300.
22. Bastos ML, Hussain H, Weyer K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first-and second-line drugs: an individual patient data metaanalysis. Clin Infect Dis 2014; 59:1364-74.
23. Falzon D, Gandhi N, Migliori GB, et al. Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. Eur Respir J 2013; 42:156-68.